July 3, 2007, Halifax, Nova Scotia – Origin BioMed Inc., a manufacturer of
over-the-counter topical drug products, announced today it has secured $3.8
million in funding, led by Calgary-based Avrio Ventures Limited Partnership,
along with co-investors Nova Scotia Business Inc. (NSBI) Venture Capital and
several private individuals. This new investment will help drive the company’s
North American market expansion, placing Origin’s leading diabetic neuropathy
products – including Neuragen®, a topical oil for fast-acting relief of diabetic foot
pain – on American drug store shelves. Origin will also open a US office as part
of this expansion. 
 
“We are extremely pleased to have Avrio Ventures as our lead investor and
partner in Origin BioMed,” said Robert Cervelli, President and Chief Executive
Officer of Origin BioMed. “Their thorough understanding of the health care and
bio-actives sectors, along with their valuable network of global contacts and
operational expertise, will help strengthen Origin's market-leading position."
 
“Origin is addressing real consumer needs and demands through plant-based
medicines and botanical drugs,” said Aki Georgacacos, general partner at Avrio
Ventures. “With its strong team, proprietary product line, and brand presence, the
company is in a great position to capitalize on the tremendous growth and
opportunity in the market for neuropathic pain relief.”